
		The St George Hospital

Print page

Research Activity 2004/05

Research project	Institution on whose behalf the research is being undertaken	Researcher	Description
CEP-10953 in patients with obstructive sleep apnoea / hypopnoea syndromes.	Cephalon.	Cistulli PA, Clark E.	Three month study of the pharmacological management of patients using continuous positive airway pressure devises with obstructive sleep apnoea / hypopnoea syndromes.
Comparison of fixed nasal continuous positive air pressure (CPAP) with modified Autoset (Resmed) device.	Respiratory Medicine, SGH.	Cistulli PA.	Comparing continuous positive airway pressure devices to improve treatment options for patients with obstructive sleep apnoea.
Comparison of S8 (Resmed Ltd) with Spirit (Resmed Ltd): a comparison of two automatic CPAP devices.	Respiratory Medicine, SGH.	Cistulli PA.	Comparing continuous positive airway pressure devices to improve treatment options for patients with obstructive sleep apnoea.
Rollover open label extension study with CEP-10953.	Cephalon.	Cistulli PA, Clark E.	12 month study of pharmacological management of patients using continuous positive air pressure (CPAP) with obstructive sleep apnoea/hypopnoea syndromes.
Prediction of oral appliance treatment outcome in obstructive sleep apnoea.	Respiratory & Sleep Medicine, SGH; UNSW; NHMRC.	Cistulli PA, Gotsopoulos H, Darendeliler MA.	Examines anatomical and physiological parameters that predict the treatment outcome associated with oral appliance therapy for obstructive sleep apnea.
Oral appliance therapy in obstructive sleep apnoea.	Respiratory & Sleep Medicine, SGH; UNSW.	Ng A, Cistulli PA.	Study of the pathophysiological mechanisms of action of oral appliance therapy in obstructive sleep apnea.
Mechanisms of action of oral appliance therapy in obstructive sleep apnoea.	NHMRC; Respiratory & Sleep Medicine, SGH; UNSW.	Zeng B, Ng A, Cistulli PA.	Using MRI scans and lung function tests to examine the mechanisms of action of oral appliance therapy in obstructive sleep apnoea.
Pneumonia severity and antibiotic guidelines in managing patients with community acquired pneumonia.	Respiratory & Sleep Medicine, SGH.	Lee R, Lindstrom ST.	To assess compliance with scoring pneumonia severity and antibiotic guidelines.
Guidelines on the early switch to oral antibiotics in managing community acquired pneumonia.	Respiratory & Sleep Medicine, SGH.	Lee R, Lindstrom S.	To examine the usefulness of a guideline on early switch to oral antibiotics in reducing intravenous antibiotic duration and length of hospital stay.
The role of palliative care in the quality of life of hospital haemodialysis patients.	Dialysis Unit, SGH.	Keen E, Tranter S, Brennan F, Martinez Y, Brown M.	To determine the benefits to patients of a palliative consultant discussing symptom control and advance care planning issues with them.
Colonic motility research program (Medtronic).	Gastroenterology Motility Research Unit, SGH.	Cook I, Dinning P, Szczesniak M, Fuentealba S.	Aims to clarify the mechanism underpinning propulsive motor patterns and how they are affected in disorders of defecation, such as severe constipation, to determine suitable treatments.
Oesophago-pharyngeal research program.	NHMRC; Gastroenterology Motility Research Unit, SGH.	Cook I, Dinning P, Szczesniak M, Fuentealba S.	Investigating the mechanisms of pharyngeal neuromuscular dysfunction in swallowing disorders, those underlying oesophago-pharyngeal regurgitation and mechanisms underpinning disordered oesophageal sensory perception.
Building a capacity for governance in the clinical workplace: evaluating clinician implementation of an end of life pathway.	Palliative Care Service, SGH.	Introna K, Sorenson R, Paull G, Donaghue J.	Evaluating the implementation of an end-of-life care pathway to improve care of the dying patient.
Frequency and characteristics of chest discomfort following coronary angioplasty and stent implantation in cardiac rehabilitation attendees.	South Eastern Sydney and Illawarra Area Health Service Cardiac Rehabilitation Outcomes Committee.	Lynch F, Paull G, Petkovski D, Connolly B, Vuong N, et al.	A multi-centre descriptive study looking at the frequency and characteristics of chest pain following coronary angioplasty and stent implantation.
A multi-centre, randomised, double-blind, controlled trial of oxygen versus air for the relief of breathlessness in terminally-ill patients with intractable dyspnoea and PaO2 > 55mmHg.	Flinders University.	Currow D, Davis JM, Paull G, Newton J, Connolly B, et al.	A study of the usefulness of oxygen or air to treat the sensation of breathlessness that is due to advanced disease when blood oxygen levels are nearly normal.
National benchmarking and evidence-based national clinical guidelines for heart failure management programs (BENCH study).	Deakin University.	Stewart S, Driscoll A, Worrell Carter L, Newton J, et al.	The aim of this research project is to develop national benchmarks and evidence-based clinical guidelines for heart failure management programs.
Providing nurse-led alternative programs, in addition to the traditional cardiac rehabilitation model, increases participation rates in a metropolitan tertiary referral hospital.	Cardiac Rehabilitation Service, SGH.	Paull G, Petkovski D, Vuong N, Connolly B, Ang E, Anderson M, Gao Y, Arndt M, Merhi Z.	Development of alternative cardiac rehabilitation programs to increase participation rates and secondary prevention opportunities.
The clinical initiative nurse: extending the role of the emergency nurse. Who benefits?	Emergency Department, SGH.	Fry M, Jones K.	Evaluation of the impact of extending the scope of practice for nurses working in the emergency department.
The characteristics and outcomes of mental health patients presenting to an emergency department over a 12-month period.	Emergency Department, SGH.	Fry M, Brunero S.	By exploring the characteristics of patient groups – in this case, mental health patients – emergency department staff can more readily target the needs of their local community, measure service performance and monitor and develop educational programs.
A retrospective review of adult mortality characteristics of patients presenting to a metropolitan tertiary emergency department.	Emergency Department, SGH.	Fry M, Rhodes-Sutton A.	Examination of an emergency department mortality rate provides a deeper understanding of service utilisation and nursing staff work performance.
A prospective study of nurse initiated Panadeine Forte: expanding pain management in the ED.	Emergency Department, SGH.	Fry M, Ryan J, Alexander N.	We identified a statistically and clinically significant reduction in post analgesic pain scores for patients. Improving pain management can have a positive impact on patients in moderate pain who experience extended waiting times prior to medical assessment.
Patients regularly leave emergency departments before medical assessment: a study of did not wait patients, medical profile and outcome characteristics.	Emergency Department, SGH.	Fry M, Thompson J, Chan A.	Examination of the rates of attendees who did not wait for treatment.
Triage nursing practice in Australian emergency departments 2002-2004: an ethnography.	The University of Sydney - PhD dissertation.	Fry M.
Thromboview in the detection of deep vein thrombosis.	Department of Nuclear Medicine, SGH.	Butler P.	This study uses radio-isotopes in the detection of calf vein deep vein thrombosis, which are not reliably detected by ultrasound.
Thromboview in the detection of pulmonary emboli.	Department of Nuclear Medicine, SGH.	Butler P.	Use of radio-isotopes in the detection of blood clots in the lungs.
Y-90 SIRT for the treatment of liver metastases from neuroendocrine tumours.	Department of Nuclear Medicine, SGH.	Quinn R.	Therapeutic treatment with radioactive microspheres injected into advanced liver tumours.
AT2 receptor response in patients with impaired glucose metabolism and the effects of different therapies.	Departments of Medicine and Endocrinology, SGH; Royal Australasian College of Physicians.	Brilliante D, O’Sullivan A, Howes L.	Those at high risk of diabetes have increased risks of vascular disease. These studies are designed to determine whether abnormal vascular function is present in at risk subjects before they develop diabetes.
A randomised controlled trial of progressive resistance training during maintenance haemodialysis (PEAK study).	Australian Kidney Foundation; Departments of Medicine, Renal Medicine and Endocrinology, SGH.	Cheema B, O’Sullivan A, Kelly J, Chan M.	Patients with chronic kidney disease have reduced muscle mass, which is related to increased mortality. These studies are designed to determine whether lifting weights will reverse the muscle wasting.
Adiponectin levels in normal and hypertensive states of pregnancy.	Departments of Medicine, Renal Medicine and Endocrinology, SGH.	O’Sullivan A, Martin A, Brown M.	Adiponectin, a hormone produced by fat cells, is being studied to determine whether blood levels change during high blood pressure states in pregnancy.
Adiponectin levels in subjects with differing oestrogen status.	Departments of Medicine, Renal Medicine and Endocrinology, SGH.	O’Sullivan A, Leung K, Lam K.	Adiponectin, a hormone produced by fat cells, levels are being studied in premenopausal women, pregnant women and post-menopausal women.
Amiodarone-induced thyrotoxicosis: left ventricular dysfunction is associated with increased mortality.	Departments of Medicine and Endocrinology, SGH.	Diamond T, O’Sullivan A.	Patients who develop an overactive thyroid while taking amiodarone have increased mortality if their heart function is poor.
Nutritional status, vascular risk factors and vascular function in chronic renal insufficiency.	Departments of Medicine, Renal Medicine and Endocrinology, SGH.	Kohlhagen J, O’Sullivan A, Kelly J.	Patients with chronic kidney disease have increased risk of heart disease. These studies are designed to determine factors which may increase their risk.
Gene regulation of platelet production.	National Health & Medical Research Council (NHMRC).	Chong B.	Blood platelet levels have to be kept within a constant range. High platelet levels may lead to thrombosis and low levels to bleeding. This project examines the regulatory mechanisms of platelet production at the gene level.
Molecular mechanism of heparin-induced thrombocytopenia and thrombosis.	National Health & Medical Research Council (NHMRC).	Chong B.	Heparin-induced thrombocytopenia and thrombosis is a serious life threatening adverse effect of heparin. This project studied the molecular mechanism of this disorder.
Molecular mechanism of drug induced immune thrombocytopenia.	National Health & Medical Research Council (NHMRC).	Chong B.	Immune thrombocytopenia is a common side effect of many drugs. This project examines the mechanism of the condition at the gene level.
Transcription regulation of cardio myocyte differentiation.	Australian Research Council (ARC).	Chong B.	This project studies the gene regulation of stem cell differentiation to heart muscle cells. It will provide innovative ideas to increase stem cell differentiation to heart muscle cells and will contribute to the development of stem cell therapy for heart disease.
Development of platelet inhibitors for the treatment of coronary disease.	Singapore National Medical Research Council.	Chong B.	This project aims to develop more anti-platelet drugs for the treatment of coronary heart disease.
Cardiovascular and metabolic outcomes following pre-eclampsia.	Departments of Medicine and Renal Medicine, SGH.	Mangos G, Pirabahaer S, Brown M.	This study has shown that woman who have had high blood pressure during their pregnancy have other cardiovascular risk factors, and higher blood pressure two to 10 years after their pregnancy. They are at higher risk of cardiovascular disease and we have shown that woman who have a pregnancy complicated by high blood pressure require ongoing follow-up with their doctor particularly with respect to the lifestyle factors that can lower their risk of future heart attack or stroke (eg exercise, healthy weight and no smoking).
Endothelial and renal abnormalities in hypertensive pregnancies.	Department of Medicine and Renal Medicine, SGH.	Holt J, Mangos G, Brown M.	We are examining novel methods of measuring urinary protein exclusion in pregnancy and are also studying a new technique of determining whether there has been damage inside blood vessels in hypertensive pregnancies. In this study we are carefully measuring kidney function in these woman.
Immune regulation, cellular trafficking and chemokine receptors in intestinal inflammation.	Department of Medicine, SGH.	Grimm M.	Mechanisms by which the gut immune system controls intestinal inflammation.
The appendix in inflammatory bowel disease.	Department of Medicine, SGH.	Grimm M.	The appendix is poorly understood but plays an important role in controlling intestinal inflammation.
Migration and positioning of lymphocytes in the hepatitis C-infected liver.	Department of Medicine, SGH; Inflammatory Diseases Research Unit, UNSW.	Grimm M.	Mechanisms by which the immune system controls hepatitis C infection and how immune cells move into the infected liver.
Infliximab in ulcerative colitis (ACT1 study).	Departments of Medicine, and Gastroenterology, SGH.	Grimm M.	A study analysing the efficacy of infliximab in ulcerative colitis.
Infliximab in ulcerative colitis (RESULTS study).	Departments of Medicine and Gastroenterology, SGH.	Grimm M.	Long-term safety study of infliximab in ulcerative colitis.
Efficacy and safety of percutaneous vertebroplasty (PV) for acute osteoporotic spinal fractures.	Department of Endocrinology, SGH; Mayne Health.	Diamond T, Clarke W.	Two-year assessment of mortality and recurrent fracture rates and pain control after PV treatment.
Percutaneous vertebroplasty versus SHAM (placebo) procedure for acute osteoporotic spinal fractures.	Department Endocrinology, SGH; Mayo Clinic; NIH.	Diamond T, Clarke W.	Assessing the benefit of cement injection verses local anaesthetics for acute spinal fractures.
Twice monthly versus once daily treatment of osteoporosis.	Department of Endocrinology, SGH; Saofi Aventis.	Diamond T, Golombic T.	Assessing whether taking tablets twice monthly is similar to once daily in maintaining bone density.
Megadose cholecalciferol for vitamin D deficiency.		Diamond T.	Investigating the benefit of a single dose of vitamin D every 12-18 months to treat vitamin D deficiency.
FEWA study.	Departments of Endocrinology, Renal Medicine and Medicine, SGH; Solvay Pharma.	Mangos G, Blomfeld J.	This trial is examining whether treatment for anaemia using erythropoietin replacement therapy (Aranesp) in kidney failure patients is effective when the treatment is administered monthly compared with fortnightly.
Professionalism and organisational culture in the medical profession.	Clinical Governance Unit, SGH; Department of Anaesthesia, SGH / UNSW; Centre for Clinical Governance Research, UNSW.	Jorm C, Braithwaite J, Kam P.	Study to determine organisational culture in medical specialists.
Phase III trial of inhaled insulin in diabetic patients.	Department of Anaesthesia and Pain Management, Royal North Shore Hospital; University of Sydney; Novo Nordisk.	Mather L, Kam P, McEduff A.	This trial will determine the efficacy and side-effects of inhaled insulin delivered by AERX system in patients with Type 2 diabetes.
Phase III trial of slow release hydromorphone in chronic pain patients.	Pain Service, SGH; MondiPharma Ltd.	Vasic A, Lee S, Kam P.	Study to determine the efficacy of slow release hydromorphone capsules in patients with chronic pain.
Early warning system and its implementation in the surgical wards.	Clinical Governance Unit, SGH; Acute Professional Nursing Department, University of Technology Sydney.	Eather B, Donoghue J, Kam P.	A research action study to evaluate the value of modified early warning system (MEWS) and to evaluate methods to implement and sustain this clinical governance project.
Neuropathic pain in chronic low back pain patients.	Palliative Medicine, Calvary Health Care Sydney; Department of Anaesthesia, SGH / UNSW.	Gorman D, Diwan DA, Kam P.	Evaluating the characteristics of neuropathic pain in chronic low back patients using an animal model to determine the mechanisms of neuropathic pain.
Mathematical modelling of blood pressure measurement errors in the management of patients with hypertension.	Departments of Anaesthetics and Public Health, University of Sydney.	Turner M, Kam P.	Study to evaluate the effect of systematic and random errors on the diagnosis of hypertension.
Organisation of anaesthetic departments in Australia.	UNSW; Department of Anaesthesia, SGH; Faculty of Business Administration, University of Canberra.	Malligan M, Kam P.	Study to determine the structure and function of different anaesthetic department models, assessing efficiency, productivity and training role.
Synoptic reporting of thyroid fine needle aspiration biopsy.	Breast Endocrine Unit, SGH.	Jamnagerwalla M, Campbell P.	Investigating the way that the results are reported and how this affects the treatment of patients.
Morbidity of hypothyroidism in II3I thyroid therapy.	Breast Endocrine Unit, SGH.	Yeung M, Campbell P.	Investing the treatment of thyroid conditions with II3I and how it effects the patient's wellbeing.
Vocal manoeuvres during nasendoscopy.	Breast Endocrine Unit, SGH.	Yeung M, Campbell P.	Examining is the most accurate way of testing for vocal cord paralysis.
Trauma service implementation.	Division of Surgery, SGH.	Ursic C.	Retrospective analysis of patient outcomes related to the implementation of full time trauma service.
Rotational flow in the proximal descending thoracic aorta during cardiopulmonary bypass.	UNSW; SGH.	Iliopoulos J, Pybus A, Horton M, Horton D, Fermanis G.	Study of the characteristics of blood flow in the aorta during bypass.
Development of an aortic wrap procedure for the treatment of heart failure.	Orthopaedic and Research Labratory, UNSW.	Iliopoulos J, Walsh WR, O’Rourke MF.	A new surgical treatment for heart failure.
Prevention of post operative retrosternal and abdominal adhesions.	UNSW; Surgical Research Laboratory, SGH.	Iliopoulos I, Walsh WR.	Prevention of post operative adhesions.
Randomised trial of nurse managed laxative protocol among post surgery colostomy patients (laxative trial).	Prince of Wales Hospital; SGH; Prince of Wales Private Hospital.	Stott C, Kittscha J, Richardson A, Graaf I, Morgan P, Fairbrother G.	Comparing early commencement of a laxative treatment following bowel surgery and existing approaches which rely on individual surgeon preference, in terms of the incidence of impaction, nurse activity and patient comfort.
Identifying the needs of patients being discharged with a newly formed ileostomy.	SGH; Wollongong University.	Kittscha J.	Identifying ileostomy complications that occur within the first month of patients being discharged from hospital, to introduce proactive approach to managing these complications.
The effects of thermal capsular shrinkage on the outcomes of arthroscopic stabilisation for primary anterior shoulder instability.	Orthopaedic Research Institute, SGH.	Chen S, Haen P, Walton J, Murrell G.	To determine if patients with traumatic, unidirectional anterior shoulder instability, who have labral repair plus arthroscopic capsular shrinkage, have better outcomes than do those receiving labral repair alone.
Topical glyceryl trinitrate application in the treatment of chronic supraspinatus tendinopathy: a randomised, double-blinded, placebo-controlled clinical trial.	Orthopaedic Research Institute, SGH.	Paoloni J, Nelson, Murrell G.	Investigating the effects of topical nitroglycerin treatment on chronic rotator cuff tendinitis, and whether this new treatment may have an adjunctive role in managing this condition.
Early inflammatory reaction after rotator cuff repair with a porcine small intestine submucosal implant: a report of four cases.	Orthopaedic Research Institute, SGH.	Malcarney H, Bonar F, Murrell G.	Investigating local inflammatory reaction in the early post-operative period following rotator cuff repair surgery with an implant.
Deletion of iNOS gene impairs mouse fracture healing.	Orthopaedic Research Institute, SGH.	Baldik Y, Diwan A, Appleyard R, Fang Z, Wang Y, Murrell G.	Evaluated the role of inducable nitric oxide synthase (iNOS) gene in healing fractures in mice.
Rotator cuff repair: an ex-vivo analysis of suture anchor repair techniques on initial load to failure.	Orthopaedic Research Institute, SGH.	Cummins C, Appleyard R, Strickland S, Haen P, Chen S, Murrell G.	Proposed to determine the best combination of anchors and suture techniques for repairing torn rotator cuff tendons.
An evaluation of the effects of the extent of capsular release and post-operative therapy on the temporal outcomes of adhesive capsulitis.	Orthopaedic Research Institute, SGH.	Diwan DB, Murrell G.	Evaluated the effects of the extent of surgical release and of post-operative physiotherapy on the outcome of this procedure in adhesive capsulitis.
Prevention of shoulder stiffness after rotator cuff repair.	Orthopaedic Research Institute, SGH.	Trenerry K, Walton J, Murrell G.	To determine whether a range of clinical and non-clinical factors played a role in preventing the development of shoulder stiffness after rotator cuff repair.
Clinical diagnosis of a superior glenoid labrum cyst with suprascapular nerve entrapment (GLEN lesion).	Orthopaedic Research Institute, SGH.	Muller M, Murrell G.	Assessed the findings of 27 clinical signs to determine which might be most useful for predicting a GLEN lesion in the shoulder.
Inhibition of urokinase receptor gene expression and cell invasion by anti-uPAR DNAzymes in osteosarcoma cells.	Orthopaedic Research Institute, SGH.	de Bock C, Lin Z, Itoh T, Morris D, Murrell G, Wang Y.	As urokinase receptor (uPAR) can promote bone metastasis. We have designed a uPAR inhibitor to block bone cancer cell invasion.
Achilles tendon healing in inducible nitric oxide synthase gene knockout mice.	Orthopaedic Research Institute, SGH.	Xia W, Appleyard R, Smythe G, Murrell G.	This project studied the role of inducible nitric oxide synthase gene in tendon healing using a gene knockout mice model.
Enhancement of collagen synthesis in tendon cells via iNOS gene transfection.	Orthopaedic Research Institute, SGH.	Xia W, Szomor Z, Wang Y, Murrell G.	Investigating whether nitric oxide could enhance collagen synthesis in human tendon cells, thereby promoting tendon healing.
The use of topically applied nitric oxide as a treatment for lateral epicondylitis in athletes.	Orthopaedic Research Institute, SGH.	Paoloni J, Appleyard R, Nelson J, Murrell G.	A review of the current literature on topical nitric oxide treatment for tennis elbow in the athletic population.
A pilot randomised controlled trial of Dexamethasone 96mg versus 16mg per day for malignant spinal cord compression treated by radiotherapy (Superdex).	Clinical Trials Unit, SGH.	Graham P.	Aiming to establish the feasibility of two different Dexamethasone doses in the management of malignant spinal cord compression, to establish safety of high dose Dexamethasone in Australia, and to test the feasibility of on-line registration and randomisation.
A randomised trial investigating the effectiveness of different durations of maximal androgen deprivation prior to and during definitive radiation therapy for locally advanced carcinoma of the prostate (TROG 96.01).	Clinical Trials Unit, SGH.	Kearsley J.	To determine whether maximal androgen deprivation, prior to and during radiation therapy, reduces the rate of local failure and appearance of metastases (cancer) that takes place after radiation therapy.
A randomised controlled trial of pain management information for cancer patients.	Clinical Trials Unit, SGH.	Lovell M.	Investigating whether an educational intervention improves knowledge and attitudes regarding pain management, anxiety levels, pain scores and quality of life, compared with standard care.
Open label, phase II trial to assess symptom control, weight change and the tolerability of Olanzapine in patients with anorexia cachexia syndrome.	Clinical Trials Unit, SGH.	Davis JM.	Determining whether Olanzepine improves symptom control and induces weight gain in patients with cancer anorexia-cachexia syndrome.
A phase III study of regional therapy in early breast cancer.	Clinical Trials Unit, SGH.	Graham P.	Comparing the standard breast radiation versus breast radiation plus regional radiation, in women with node positive or high risk node-negative breast cancer treated by lumpectomy, partial mastectomy, axillary surgery and systemic therapy.
Phase I trial of NV-06 in combination with Cisplatin or Carboplatin in patients with advanced malignancies.	Clinical Trials Unit, SGH; Edward Marshall Pty Ltd.	de Souza P.	To determine the recommended dose of oral Phenoxodiol when given together with Cisplatin or Carboplatin in three week cycle.
Phase II trial of intravesical Gemcitabine in patients with transitional cell carcinoma.	Clinical Trials Unit, SGH.	de Souza P.	Determining the therapeutic response rate to intravesical Gemcitabine in patients with transitional cell carcinoma of bladder.
Phase 1a bio-availability, pharmacokinetic and acute safety study of both oral and IV dosage forms of NV18 in patients with solid tumours.	Clinical Trials Unit, SGH; Edward Marshall Pty Ltd.	de Souza P.	To determine the bio-availability, safety and tolerability of NV18 when administered either orally or intravenously.
An international, multi-centre, double blind, double dummy, phase III, two arm adjuvant trial comparing Letrozole versus Tamoxifen in post menopausal women with operable breast cancer.	Clinical Trials Unit, SGH; Breast International Group.	de Souza P.	To compare the overall survival, disease free survival and safety of using Letrozole and Tamoxifen as adjuvant therapy for postmenopausal breast cancer patients with hormone receptor positive tumours.
A phase III, three arm, randomised, open label study of Interferon Alfa alone, CCI-779 alone and in combination of Interferon Alfa and CCI-779 in first line poor prognosis subjects with advanced renal cell carcinoma.	Clinical Trials Unit, SGH; Wyeth Research.	de Souza P.	Comparing the overall survival of patients treated with CCI-779 and combination of CCI and interferon and interferon alone, in poor prognosis patients with advanced renal cell carcinoma.
Weekly Carboplatin-Taxol and concomitant irradiation for locally advanced NSCLC: predictors of treatment tolerance.	Clinical Trials Unit, SGH.	Links M.	Predicting treatment failure due to toxicity and to determine the efficacy and toxicity of Carboplatin-Taxol and Concomitant irradiation in a NSW setting.
Phase II study of Docetaxol and Celecoxib as first or second line therapy in patients with advanced NSCLC.	Clinical Trials Unit, SGH.	Links M.	To determine the response rate and toxicity of the regimen.
Phase II trial of Gemcitabine and Docetaxel in anthracycline-exposed patients with advanced or metastatic breast cancer.	Clinical Trials Unit, SGH.	Links M.	Determining the objective response rate in patients with advanced or metastatic breast cancer who are treated with Gemcitabine and Docetaxel.
Randomised, placebo controlled, double blind, phase II study of Docetaxel compared to Docetaxel plus LY335979 as first line therapy in women with metastatic or locally recurrent breast cancer who have received one prior chemotherapy regimen.	Clinical Trials Unit, SGH.	de Souza P.	Investigating treatment regimes in women with metastatic or locally recurrent breast cancer who have previously received one chemotherapy regimen in the neoadjuvant or adjuvant setting.
Multi-centre, Phase III, randomised trial comparing Docetaxel in combination with Doxorubicin and Cyclophosphamide versus Doxorubicin and Cyclophosphamide followed by Docetaxel as adjuvant treatment of operable breast cancer HER 2 negative patients with positive axillary lymph nodes.	Clinical Trials Unit, SGH.	Links M.	To compare disease free survival after different treatment regimes in operable adjuvant breast cancer HER 2 negative patients with positive axillary lymph nodes.
Multi-centre, Phase III, randomised trial, comparing Doxorubicin and Cyclophosphamide followed by Docetaxol with Doxorubicin and Cyclophosphamide followed by Docetaxol and Trastuzumab and with Docetaxol, platinum salt and Trastuzumab in the adjuvant treatment of node positive and high risk node negative patients with operable breast cancer containing the HER 2 alteration.	Clinical Trials Unit, SGH.	Links M.	Comparing disease free survival after different treatment regimes in the adjuvant treatment of node positive and high risk node negative patients with operable breast cancer containing the HER 2 alteration.
Plasma and intracellular pharmacokinetics of Gemcitabine and correlation with polymorphisms in Cytidine Deaminase: 100mg versus 30mg infusion.	Clinical Trials Unit, SGH.	Links M.	Exploring the effects of two schedules of Gemcitabine administration.
First line treatment of postmenopausal metastatic breast cancer - a randomised, multi-centre study comparing concurrent versus sequential chemoendocrine therapy with Letrozole versus. Letrozole single agent (FEMALE).	Clinical Trials Unit, SGH; Novartis.	de Souza P.	To compare the time to progression of standard front-line chemotherapy in combination or followed by different drug therapies.
Phase I, dose escalation study of oral Abendazole in patients with cancer refractory to conventional treatments.	Clinical Trials Unit, SGH.	Links M, Morris D.	A dose finding study for a novel cancer agent that has the potential to interfere with cancer cell growth and blood supply.
Phase III, randomised, inter-group, international trial assessing the clinical activity of STI571 at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumours (GIST) expressing the GIT receptor tyrosine kinase.	Clinical Trials Unit, SGH.	Links M.	Gastrointestinal stromal tumours are a rare disease with no known effective chemotherapy. STI571 has proved itself an effective treatment which is easy to administer.
A phase 2a trial to determine the preliminary efficacy, safety and tolerance of IV KW2170 administered once weekly for three weeks to patients with recurrent or advanced hormone refractory carcinoma of the prostate who have failed standard therapeutic regimens.	Clinical Trials Unit, SGH.	de Souza P.	KW2170 is an intravenous chemotherapy used to treat hormone resistant metastatic prostate cancer, a disease which has traditionally failed to respond to such an approach.
Phase II study of Gemcitabine integrated with concomitant 5FU and 3D conformal radiotherapy, for the treatment of localised pancreatic cancer.	Clinical Trials Unit, SGH.	Graham P.	Pancreatic cancer has a poor prognosis. This trial aims to determine if the standard treatments of radiotherapy and chemotherapy can be used more effectively together.
A randomised, double-blind, placebo-controlled, parallel group pilot study to assess the efficacy, safety and tolerability of YM598 in combination with mitoxantrone and prednisone in androgen independent prostate cancer patients with bone pain.	Clinical Trials Unit, SGH.	de Souza P.	YM598 is a novel drug with potential to help with the pain that can be experienced by patients who have prostate cancer which has spread to the bones.
A phase III, randomised, study of Cetuximab and best supportive care versus best supportive care, in pre-treated metastatic colorectal cancer.	Clinical Trials Unit, SGH.	Links M, Liauw W.	Cetuximab is one of a new class of drugs called mono-clonal antibodies that has the potential to treat colon cancer in patients who have failed every other available treatment.
Brain metastases radiation randomised fractionation study.	Clinical Trials Unit, SGH.	Graham P.	To determine which of the two radiation fractionation schemes is superior in the treatment of brain metastases.
A randomised comparison of breast conservation with or without lumpectomy radiotherapy boost.	Clinical Trials Unit, SGH.	Graham P.	To compare which of the radiation schemes is superior in the treatment of breast conservation with or without lumpectomy radiotherapy boost.
Tumour volume as an independent prognostic factor in patients with non-small cell lung cancer: a protocol for a prospective database.	Clinical Trials Unit, SGH.	Graham P.	Determining the effect on the size of surviving tumour in patients with locoregional, non-small cell, lung cancer treated by definitive radiotherapy, after adjusting for the effect of current TNM staging system and other known predictive factors such as weight loss.
A paired, double-blind, randomised, comparison of Cavilon Durable Barrier Cream to 10% Glycerine (Sorbolene) Cream in the prophylactic management of post-mastectomy irradiation skin care (Cavilon).	Clinical Trials Unit, SGH.	Graham P.	To evaluate whether peak and overall skin reactions may be reduced by Cavilon Durable Barrier Cream compared to Sorbolene.
A randomised trial investigating the effect on biochemical (PSA) control and survival of different duration of adjuvant androgen deprivation, in association with definitive radiation treatment for localised carcinoma of the prostate (RADAR).	Clinical Trials Unit, SGH.	Bucci J.	To determine whether 18 months of androgen deprivation therapy with radiation therapy improves relapse-free survival, overall survival, reduces local failure and improves quality of life compared to the standard six months with radiotherapy. Also, to determine whether bisphosphonate therapy will reduce osteopenic fractures, improve bone mineral density, delay bony metastases and improve quality of life.
Evaluation of two doses of SR31747A (75mg and 125mg) in non-metastatic androgen-independent prostate cancer, randomised, double-blind, placebo-controlled Phase II study (Odyssey).	Clinical Trials Unit, SGH; Sanofi-Synthelabo.	de Souza P.	To estimate the efficacy of SR31747A given at different doses versus placebo in androgen independent prostate cancer patients without distant metastases with time to clinical progression.
A double-blind placebo-controlled trial of Zoloft’s effects on symptoms and survival time in advanced cancer (Zest).	Clinical Trials Unit, SGH; NHMRC.	Links M.	Investigating whether an anti-depressant improves well-being and survival in people with advanced cancer who felt depressed, anxious or tired, but do not have major depression.
Combination chemotherapy with Gemcitabine and Oxaliplatin for advanced non-small cell lung cancer: a randomised Phase II sequencing study.	Clinical Trials Unit, SGH.	Links M.	Determining the response rate of this combination regimen, the effect of drug sequence on the toxicity, efficacy and pharmacokinetics of these drugs, and progression-free and overall survival.
An expanded access program of TarcevaÒ (Erlotinib) in patients with advanced stage IIIB/IV non-small cell lung cancer.	Clinical Trials Unit, SGH.	de Souza P.	Describing the activity and tolerability of Tarceva in this patient population assessing: best response, time to progression, survival and safety.
A Phase 3, double-blind, placebo-controlled study of maintenance Pemetrexed plus best supportive care (BSC) versus best supportive care immediately following induction treatment for advanced non-small cell lung cancer (NSCLC).	Clinical Trials Unit, SGH.	de Souza P.	To compare maintenance therapies in terms of the overall survival time in patients with Stage IIB or IV NSCLC who have not progressed during four cycles of platinum-based induction chemotherapy.
A collaborative randomised phase III trial: the timing of intervention with androgen deprivation in prostate cancer patients with a rising prostate-specific antigen PSA (TOAD).	Clinical Trials Unit, SGH.	Bucci J.	The purpose of this trial is to determine whether immediate treatment with androgen deprivation therapy (ADT) following a rising PSA blood test, is better or worse than delayed treatment with ADT, in terms of prolonging lifespan, balanced against the effects on quality of life in men diagnosed with adenocarcinoma of the prostate.
A Phase III trial evaluating the role of ovarian function suppression and the role of Exemestane as adjuvant therapies for suppression, and the role of Exemestane as adjuvant therapies for premenopausal women with endocrine responsive responsive breast cancer (SOFT).	Clinical Trials Unit, SGH; Australia and New Zealand Breast Cancer Trial Group.	Lynch J.	Comparing treatments for breast cancer.
Pilot for randomised comparison of Anastrozole commenced before and continued during adjuvant radiotherapy for breast cancer, versus Anastrozole and subsequent anti-estrogen therapy delayed until radiotherapy (STARS).	Clinical Trials Unit, SGH.	Graham P	The study aims to reduce the five year in-field radiotherapy failure rate by half, as well as avoid the potential local radiotherapy toxicity enhancements of the previous standard hormone therapy Tamoxifen.
A Phase III, randomised, open-label, multi-centre study comparing GW572016 and Capecitabine (Xeloda) versus Capecitabine in women with refractory advanced or metastatic breast cancer.	Clinical Trials Unit, SGH; GlaxoSmithKline.	Lynch J.	To evaluate and compare time to progression in subjects with refractory advanced or metastatic breast cancer treated with GW572016 and Capecitabine versus Capecitabine alone.
Molecular basis of radiosensitivity.	Department of Radiation Oncology, SGH.	Clarke R.	Radiosensitivity testing of cell lines derived from clinically radiosensitive patients and patients with Lupus.
Affects of Anastrozole on cellular response to radiation	Department of Radiation Oncology, SGH.	Clarke R.	Radiosensitivity testing of the breast cancer treatment Anastrozole.
ATM gene expression in recurrent breast cancers after radiotherapy.	Department of Radiation Oncology, SGH; Queenland Institute of Medical Research, Brisbane.	Clarke R.	Investigating breast cancer tumour suppressor gene in recurrent breast cancers before and after radiotherapy.
ATM gene signalling in a radioresistant myoepithelioma cell line with strong cytoplasmic ATM gene expression.	Department of Radiation Oncology, SGH; Queenland Institute of Medical Research, Brisbane.	Clarke R.	We have generated a cell line from a rare and radioresistant malignant cancer of the breast with an unusual pattern of ATM gene expression that may impact the gene signalling.
Genetic basis of familial prostate cancer.	Department of Radiation Oncology and the Prostate Cancer Institute, SGH.	Clarke R.	Screening familial and sporadic prostate cancer patient blood samples for definitive markers of prostate cancer.
Genetic basis of spinal fusion.	Orthopaedic Research Institute and Radiation Oncology, SGH.	Clarke R.	Screening Kippel-Feil Syndrome patients for mutations in the sgm1 gene responsible for spinal integrity.
Targeted alpha therapy.	Centre for Experimental Radiation Oncology, SGH; UNSW Clinical School.	Allen BJ, Rizv S, Li Y, Song E, Qu CF.	Development of a new approach to cancer therapy.
Pancreatic cancer.	Centre for Experimental Radiation Oncology, SGH; UNSW Clinical School.	fa Qu C, et al	Preclinical studies of targeted alpha therapy for pancreatic cancer to determine the effectiveness of the therapy.
Ovarian Cancer.	Centre for Experimental Radiation Oncology, SGH; UNSW Clinical School.	Song E, et al	Preclinical studies of targeted alpha therapy for ovarian cancer to determine the effectiveness of the therapy.
Intralesional clinical trial of targeted alpha therapy (TAT) for melanoma.	Centre for Experimental Radiation Oncology, SGH; UNSW Clinical School.	Allen BJ, Graham P, et al.	Testing the effects of escalating doses of TAT into skin melanomas.
Systemic clinical trial of targeted alpha therapy (TAT) for melanoma.	Centre for Experimental Radiation Oncology, SGH; UNSW Clinical School.	Allen BJ, Graham P, et al.	Testing the effects of intravenous injections of TAT.
Multiple targeted alpha therapy for prostate cancer.	Centre for Experimental Radiation Oncology, SGH; UNSW Clinical School.	Li Y, et al	Different targeting vectors are tested in mouse models.
TAT with Herceptin for breast cancer.	Centre for Experimental Radiation Oncology, SGH; UNSW Clinical School; NHMRC.	Song E, et al.	Investigating breast cancer treatments.
Implementation of Internal Atomic Energy Agency TRS-398 dosimetry protocol based on dose-to-water standard.	Cancer Care Centre, SGH; University of Wollongong.	Feng Qin C.	Implementing a protocol that relates to linear accelerator radiation levels.
Comparison between Nucletron's Plato and Swift software for high dose radiation.	Cancer Care Centre, SGH.	Howie A.	A comparison of traditional planning technique versus real-time planning of prostate brachytherapy cancer treatments.
A double-paired blind, randomised, comparison of Cavilon Durable Barrier Cream™ to 10% glycerine (Sorbelene) cream in the prophylactic management of post-mastectomy irradiated skin care.	Cancer Care Centre, SGH.	Graham P, Gupta R, Parris A.	Using thermo luminaescence dossimetry to measure the skin dose under “jelly” bolus, to see if the skin reaction is due to cream or the incident dose is high in the area.
Prostate brachytherapy rectal probe development.	Cancer Care Centre, SGH; University of Wollongong.	Howie A, Gupta R, Rosenfeld A, Boehm J.	Development of a detector to determine the radiation dose to the rectum during prostate brachytherapy procedures.
Comparison of imaging techniques for high dose radiation prostate brachytherapy.	Cancer Care Centre, SGH.	Howie A, Bucci J.	Comparison of ultrasound, CT and MRI for high dose radiation prostate brachytherapy imaging.
Verification of doses delivered to the tumour and critical structures in prostate brachytherapy using thermoluminescence dosimeters.	Prostate Cancer Institute, SGH.	Duggan L, Bucci J, Enari E, Rosenfeld A, Cutajar D.	Measurement of the dose distribution in the tumour during prostate brachytherapy.
Quality assurance of low dose radiation and high dose radiation prostate brachtherapy.	University of Wollongong; Cancer Care Centre, SGH.	Bucci J, Duggan L, Enari E, Rule G.	Design of new detectors for quality assurance in prostate brachytherapy.
PCR analysis of paraffin embedded tissue for synovial sarcoma gene fusion.	Medical Oncology, SGH.	Johnson L, Tran K, de Souza P.	Diagnosis of synovial sarcoma can be difficult. We are attempting to extract RNA from paraffin embedded tissue in order to study the gene rearrangements in this disease.
Phase I study of Phenoxodiol and Carboplatin or Cisplatin in patients with advanced cancer.	Medical Oncology, SGH.	Links M, Liauw W, Chan C, Howes L, de Souza P.	This trial of a novel drug and Cisplatin / Carboplatin was designed from work in our laboratory that showed the combination was promising against a variety of cancer cells.
Enhancement of isoflavone activity in vitro with standard chemotherapy drugs.	Medical Oncology, SGH.	McPherson R, de Souza P.	In our laboratory, we showed that the combination of a novel isoflavone compound and Cisplatin was synergistic against a variety of cancer cells, including prostate cancer.
Analysis of PSA response to docetaxel and carboplatin in men with hormone refractory prostate cancer.	Medical Oncology, SGH.	Grimison P, Kaplan J, de Souza P.	Docetaxel is a promising new chemotherapy drug for prostate cancer. We were interested in examining the pattern of PSA responses in men with this disease.
The role of ras signal transduction perturbation in prostate cancer cells.	Medical Oncology, SGH.	Li S, de Souza P.	Prostate cancer cells are dependent on cell signalling to survive and grow. We are interested in finding novel ways to disrupt this signalling using chemotherapy and non–chemotherapy drugs in order to enhance cell kill.
Phase II trial of intravesical Gemcitabine in patients with superficial bladder cancer.	Medical Oncology, SGH.	de Souza P, Cozzi P, Lynch W, Begbie S, Hovey L, Briscoe K.	This study is being carried out in a number of cancer centres in NSW. We are interested in examining the response rate of Gemcitabine when given directly into the bladder in patients with early bladder cancer.
Activity of PLA2 inhibitors in prostate cancer cell lines.	Medical Oncology, SGH; Department of Urological Research, USYD.	Patel M, Dong Q, de Souza P.	Testing a variety of phospholipase inhibitors against prostate cancer cells in the laboratory to find combinations that produced synergy.
Investigation of the binding of Tc-99m MIBI (sestaMIBI) to multiple myeloma plasma cells.	Departments of Clinical Haematology and Nuclear Medicine, SGH.	Hicks C, Johnstone M, Butler P, Kwan YL, Manoharan A.	An investigation examining the ex vivo binding of the radiopharmaceutical sestaMIBI which can detect areas of active disease in patients with multiple myeloma.
Stem cell subsets and engraftment prediction in multiple myeloma patients undergoing autologous stem cell transplantation.	Departments of Clinical Haematology & Haematology, South Eastern Area Laboratory Service (SEALS).	Hicks C, Abdallah A, Wong R, Manoharan A, Kwan YL.	Evaluating alternative viable stem cell markers in the transplanted stem cells product and their relationship to engraftment kinetics of transplanted patients.
Correlation between viable CD34 (+) stem cells and colony-forming units -GM (CFU-GM) and haemopoietic engraftment kinetics after peripheral blood stem cell transplantation.	Departments of Clinical Haematology & Haematology, South Eastern Area Laboratory Service (SEALS).	Hicks C, Abdallah A, Wong R, Manoharan A, Kwan YL.	A single centre study to investigate whether viable haemopoietic stem cells and / or colony-forming units -GM are predictive factors of the rate of haemopoietic engraftment after peripheral blood stem cell transplantation.
Gene expression studies in patients with multiple myeloma.	Department of Clinical Haematology, South Eastern Area Laboratory Service (SEALS).	Wong R, Kwan YL, Manoharan A.	To investigate how the abnormal expression of the Pax 5 gene in patients’ with myeloma (malignant tumour) contributes to the individual’s response to treatment and to establish a correlation between such abnormal gene expression and clinical diagnosis.
Once-daily oral direct Factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis. (The Einstein-DVT dose-finding study).	Departments of Clinical Haematology & Medicine, UNSW.	Brighton T, Chong B.	New oral anticoagulant in deep vein thrombosis treatment.
ODIXa_DVTOral Direct Factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep vein thrombosis (ODIXa-DVT Study): a Phase II dose finding and proof of principle trial.	Departments of Clinical Haematology & Medicine, UNSW.	Brighton T, Chong B	New oral anticoagulant in deep vein thrombosis treatment.
A trial of Dalteparin low molecular weight Heparin for primary prophylaxis of venous thromboembolism in brain tumour patients (PRODIGE).	Departments of Clinical Haematology & Medicine, UNSW.	Brighton T, Chong B.	Long term deep vein thrombosis prophylaxis in brain tumour patients.
A phase III, randomised, parallel-group, double-blind, active controlled study to investigate the efficacy and safety of two different dose regimens of orally administered dabigatran etexilate capsules [150 or 220 mg once daily starting with a half dose (ie 75 or 110 mg) on the day of surgery] compared to subcutaneous enoxaparin 40 mg once daily for 8 ± 2 days, in prevention of venous thromboembolism in patients with primary elective total knee replacement surgery (REMODEL).	Department Clinical Haematology & Department of Medicine UNSW.	Brighton T, Chong B.	New oral anticoagulant in deep vein thrombosis prophylaxis - knee surgery.
A Phase III, randomised, parallel group, double-blind, active controlled study to investigate the efficacy and safety of two different dose regimens of orally administered dabigatran etexilate capsules [150 or 220 mg once daily starting with half dose (ie 75 or 110mg) on the day of surgery] compared to subcutaneous enoxaparin 40mg once daily for 28-35 days, in prevention of venous thromboembolism in patients with primary elective total hip replacement surgery (RENOVATE).	Departments of Clinical Haematology & Medicine. UNSW.	Brighton T, Chong B.	New oral anticoagulant for deep vein thrombosis prevention following hip surgery.
A multi-centre, international, randomised, open-label, assessor-blind, non-inferiority study comparing the efficacy and safety of once-weekly subcutaneous SanOrg34006 with the combination of (LMW) Heparin and vitamin K antagonist (VKA) in the treatment of acute symptomatic deep vein thrombosis (VAN GOGH DVT).	Departments of Clinical Haematology & Medicine. UNSW.	Brighton T, Chong B.	New weekly subcutaneous anticoagulant in deep vein thrombosis treatment.
A multi-centre, international, randomised, open-label, assessor-blind, non-inferiority study comparing the efficacy and safety of once-weekly subcutaneous SanOrg34006 with the combination of (LMW) Heparin and vitamin K antagonist (VKA) in the treatment of acute symptomatic pulmonary embolism (VAN GOGH PE).	Departments of Clinical Haematology & Medicine. UNSW.	Brighton T, Chong B.	New weekly subcutaneous anticoagulant in pulmonary embolism treatment.
A multi-centre, international, randomised, double-blind, study comparing the efficacy and safety of once-weekly subcutaneous SanOrg34006 with placebo in the long-term prevention of symptomatic venous thromboembolism in patients with symptomatic pulmonary embolism or deep-vein thrombosis who completed six months of treatment with vitamin K antagonist or SanOrg34006 (VAN GOGH EXT).	Departments of Clinical Haematology & Medicine. UNSW.	Brighton T, Chong B.	New weekly subcutaneous anticoagulant in deep vein thrombosis and pulmonary embolism extended treatment.
Asprin to prevent recurrent venous thromboembolism. A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial oral anticoagulation to prevent recurrent venous thromboembolism (ASPIRE).	Department of Clinical Haematology, UNSW.	Brighton T.	Use of Aspirin to prevent deep vein thrombosis recurrence.
A double-blind, placebo-controlled, parallel, multi-centre study on extended VTE prophylaxis in acutely ill patients with prolonged immobilisation (EXCLAIM).	Departments of Clinical Haematology & Medicine. UNSW.	Brighton T, Chong B.	Long term deep vein thrombosis prevention in medical patients.
A multi-centre, randomised Phase III study of low-dose Thalidomide, Prednisolone and Zoledronic Acid versus Prednisolone and Zoledronic Acid for post-ASCT maintenance therapy in patients with multiple myeloma (ALLG-MM6).	Department Clinical Haematology, UNSW.	Brighton T, Chong B.	Use of thalidomide in ASCT maintenance in multiple myleloma (malignant tumour).
Building a capacity for workplace governance: evaluating clinician implementation of an end of life care pathway.	Palliative Care Department, SGH.	Introna K, Paull G, Sorenson R, Donoghue J, Davis JM.	To assess, describe and document the implementation of an end-of-life care pathway across six wards at SGH, to improve the care of the dying patient and to describe the organisation capacity needed to effect clinical change.
A double-blind, randomised, study of oxygen versus air in oxygen naïve patients with refractory dyspnoea and PaO2>55.	Flinders University, South Australia; Palliative Care Department, SGH; Calvary Health Care Sydney.	Davis JM.	A multi-centre study of the usefulness of oxygen or air to treat the sensation of breathlessness that is due to advanced disease when blood oxygen levels are nearly normal.
Smile movement project: a multidisciplinary falls prevention program, project 2.	Aged Care Precinct, SGH.	Donoghue J, Mitten-Lewis S, Murphy M, Brookes K.	Using an upper body movement program and monitoring cognitive status to reduce patient falls on the aged care ward.
Comparing the usefulness of two pain intensity rating scales for culturally and linguistically diverse patients.	Diversity Health, Clinical Governance & Nursing Units, SGH; Multicultural Health Unit, SESIAHS.	Mitten-Lewis S, Challita V.	Patient interviews and nursing practice development to establish effective pain assessments for non-English speaking patients.
The effect of interdepartmental transfers on hospital acquired infections in elective orthopaedic, cardiothoracic and vascular patients.	HCF Health & Medical Foundation; Department of Microbiology, South Eastern Sydney Laboratory Service (SEALS).	Blay N, Quoyle C, Curd S.	The study incorporates pre and post operative nasal and wound swabbing. Patients’ interdepartmental transfers are tracked to identify if a significant relationship exists between multi resistant stapphylococchus aureus and transfer.
Implementing the end of life pathway on six wards at St George hospital.	SGH; University of Technology, Sydney.	Introna K, Paull G, Sorensen R, Donoghue J.	Investigating the provision of end-of-life services and support given to patients who die at SGH.
Keeping well in chronic illness.	The University of Technology Sydney; SGH.	Donoghue J, Gallagher R, Chenoweth L, Stein-Parbury J Mitten-Lewis S, Higgins C, Davidson S, Kotobalavu K.	Interviewing patients with a chronic illness about their self care behaviours, monitoring of their condition, confidence and life orientation.
Post operative pain intensity and self-efficacy in older patients’ use of patient controlled analgesia.	University of Technology, Sydney; SGH.	Melbourne G, Donoghue J, Gallagher R.	The research is trying to identify if there is a significant relationship between older patients’ use of patient controlled analgesia and their level of confidence to manage their own pain.
From machine to patient: shifting the focus of care within a hospital haemodialysis unit.	University of Technology, Sydney.	Tranter S, Donoghue J, Baker J.	Ethnographic study of the patients, nurses and medical staff followed by practice development.
Evaluation of self care, self efficacy and quality of life for people using a Chait caecostomy catheter.	SGH; St George Private Hospital.	Patton V, Donoghue J, Lubowski D, Thompson J.	Study of self care behaviours, self efficacy and quality of life for people who have a Chait catheter implanted to manage faecal incontinence.
Pain management in substance use persons following orthopaedic trauma and surgery.	SGH.	Blay N, Kent A, Bubnij S, Lee S, Arthur D.	Analysis of post operative analgesic efficacy for orthopaedic patients who are substance users, and practice development with ward staff.
Failure to rescue following major gut surgery and the introduction of the modified early warning system (MEWS) system to manage these patients.	University of Technology, Sydney.	Eather B, Donoghue J, Kam P.	The study introduced a scoring scheme to nurses and doctors to identify patients whose condition deteriorated following surgery and communicate this information so that the patient’s condition is managed appropriately.
Wound healing over three months following the excision of a sacral pilonidal sinus.	SGH, St George Private Hospital; The Sutherland Hospital.	Stewart A, Donoghue J, Mitten Lewis S, Melbourne G, Rogan F, Wyllie A.	Descriptive study of patients’ wounds and psychosocial factors after the excision of a sacral pilonidal sinus.
Investigation of post stent pain following angioplasty.	The Sutherland, St George and Prince of Wales Hospitals.	Lynch F, Gallagher R.	Descriptive survey of patients’ experiences of pain following stent insertion.